0001551152-22-000045 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Oct. 26, 2022
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,768,480,508
NEW YORK STOCK EXCHANGE, INC. \| Common stock
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.500 Senior Notes Due 2023
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.500% Senior Notes due 2023
Trading Symbol	ABBV23B
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.375 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
NEW YORK STOCK EXCHANGE, INC. \| Sec 0.750 Senior Notes Due 2027
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.625 Senior Notes Due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
NEW YORK STOCK EXCHANGE, INC. \| Sec 2.125 Senior Notes Due 2029
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
NEW YORK STOCK EXCHANGE, INC. \| Sec 1.250 Senior Notes due 2031
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
CHICAGO STOCK EXCHANGE, INC \| Common stock
Entity Information
Security Exchange Name	CHX
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net revenues	$ 14,812	$ 14,342	$ 42,933	$ 41,311
Cost of products sold	5,022	4,390	13,244	13,126
Selling, general and administrative	3,304	3,083	11,843	9,089
Research and development	1,614	1,661	4,720	5,095
Acquired IPR&D and milestones	40	402	454	719
Other operating expense, net	229	500	57	432
Total operating costs and expenses	10,209	10,036	30,318	28,461
Operating earnings	4,603	4,306	12,615	12,850
Interest expense, net	497	585	1,568	1,813
Net foreign exchange loss	36	12	108	35
Other expense (income), net	(330)	21	427	2,284
Earnings before income tax expense	4,400	3,688	10,512	8,718
Income tax expense	448	508	1,139	1,214
Net earnings	3,952	3,180	9,373	7,504
Net earnings attributable to noncontrolling interest	3	1	10	6
Net earnings attributable to AbbVie Inc.	$ 3,949	$ 3,179	$ 9,363	$ 7,498
Per share data
Basic earnings per share (in dollars per share)	$ 2.22	$ 1.78	$ 5.26	$ 4.21
Diluted earnings per share (in dollars per share)	$ 2.21	$ 1.78	$ 5.24	$ 4.19
Weighted-average basic shares outstanding (in shares)	1,771	1,770	1,771	1,769
Weighted-average diluted shares outstanding (in shares)	1,776	1,777	1,777	1,776

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,952	$ 3,180	$ 9,373	$ 7,504
Foreign currency translation adjustments, net of tax expense (benefit) of $(11) for the three months and $(30) for the nine months ended September 30, 2022 and $(8) for the three months and $(32) for the nine months ended September 30, 2021	(989)	(361)	(2,043)	(794)
Net investment hedging activities, net of tax expense (benefit) of $165 for the three months and $348 for the nine months ended September 30, 2022 and $51 for the three months and $123 for the nine months ended September 30, 2021	599	184	1,265	444
Pension and post-employment benefits, net of tax expense (benefit) of $14 for the three months and $35 for the nine months ended September 30, 2022 and $17 for the three months and $50 for the nine months ended September 30, 2021	60	67	136	196
Cash flow hedging activities, net of tax expense (benefit) of $14 for the three months and $17 for the nine months ended September 30, 2022 and $13 for the three months and $16 for the nine months ended September 30, 2021	83	57	98	115
Other comprehensive loss	(247)	(53)	(544)	(39)
Comprehensive income	3,705	3,127	8,829	7,465
Comprehensive income attributable to noncontrolling interest	3	1	10	6
Comprehensive income attributable to AbbVie Inc.	$ 3,702	$ 3,126	$ 8,819	$ 7,459

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (11)	$ (8)	$ (30)	$ (32)
Net investment hedging activities, tax expense (benefit)	165	51	348	123
Pension and post-employment benefits, tax expense (benefit)	14	17	35	50
Cash flow hedging activities, tax expense (benefit)	$ 14	$ 13	$ 17	$ 16

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and equivalents	$ 11,832	$ 9,746
Short-term investments	47	84
Accounts receivable, net	10,743	9,977
Inventories	3,172	3,128
Prepaid expenses and other	4,570	4,993
Total current assets	30,364	27,928
Investments	235	277
Property and equipment, net	4,893	5,110
Intangible assets, net	68,725	75,951
Goodwill	31,726	32,379
Other assets	5,382	4,884
Total assets	141,325	146,529
Current liabilities
Short-term borrowings	10	14
Current portion of long-term debt and finance lease obligations	9,197	12,481
Accounts payable and accrued liabilities	23,505	22,699
Total current liabilities	32,712	35,194
Long-term debt and finance lease obligations	60,399	64,189
Deferred income taxes	1,972	3,009
Other long-term liabilities	30,215	28,701
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,973,038 shares issued as of September 30, 2022 and 1,803,195,293 as of December 31, 2021	18	18
Common stock held in treasury, at cost, 44,572,117 shares as of September 30, 2022 and 34,857,597 as of December 31, 2021	(4,590)	(3,143)
Additional paid-in capital	19,056	18,305
Retained earnings	4,953	3,127
Accumulated other comprehensive loss	(3,443)	(2,899)
Total stockholders' equity	15,994	15,408
Noncontrolling interest	33	28
Total equity	16,027	15,436
Total liabilities and equity	$ 141,325	$ 146,529

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,812,973,038	1,803,195,293
Common stock held in treasury, at cost (in shares)	44,572,117	34,857,597

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2020	$ 13,097	$ 18	$ (2,264)	$ 17,384	$ 1,055	$ (3,117)	$ 21
Beginning balance (in shares) at Dec. 31, 2020		1,765
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	7,498	$ 0	0	0	7,498	0	0
Other comprehensive income (loss), net of tax	(39)	0	0	0	0	(39)	0
Dividends declared	(6,953)	0	0	0	(6,953)	0	0
Purchases of treasury stock	(803)	$ 0	(803)	0	0	0	0
Purchases of treasury stock (in shares)		(7)
Stock-based compensation plans and other	771	$ 0	47	724	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	6	$ 0	0	0	0	0	6
Ending balance at Sep. 30, 2021	13,577	$ 18	(3,020)	18,108	1,600	(3,156)	27
Ending balance (in shares) at Sep. 30, 2021		1,768
Beginning balance at Jun. 30, 2021	12,594	$ 18	(3,022)	17,936	740	(3,103)	25
Beginning balance (in shares) at Jun. 30, 2021		1,767
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	3,179	$ 0	0	0	3,179	0	0
Other comprehensive income (loss), net of tax	(53)	0	0	0	0	(53)	0
Dividends declared	(2,319)	0	0	0	(2,319)	0	0
Purchases of treasury stock	(6)	$ 0	(6)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	180	$ 0	8	172	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	2	$ 0	0	0	0	0	2
Ending balance at Sep. 30, 2021	13,577	$ 18	(3,020)	18,108	1,600	(3,156)	27
Ending balance (in shares) at Sep. 30, 2021		1,768
Beginning balance at Dec. 31, 2021	15,436	$ 18	(3,143)	18,305	3,127	(2,899)	28
Beginning balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	9,363	$ 0	0	0	9,363	0	0
Other comprehensive income (loss), net of tax	(544)	0	0	0	0	(544)	0
Dividends declared	(7,537)	0	0	0	(7,537)	0	0
Purchases of treasury stock	(1,483)	$ 0	(1,483)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	787	$ 0	36	751	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	5	$ 0	0	0	0	0	5
Ending balance at Sep. 30, 2022	16,027	$ 18	(4,590)	19,056	4,953	(3,443)	33
Ending balance (in shares) at Sep. 30, 2022		1,768
Beginning balance at Jun. 30, 2022	14,688	$ 18	(4,591)	18,906	3,516	(3,196)	35
Beginning balance (in shares) at Jun. 30, 2022		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	3,949	$ 0	0	0	3,949	0	0
Other comprehensive income (loss), net of tax	(247)	0	0	0	0	(247)	0
Dividends declared	(2,512)	0	0	0	(2,512)	0	0
Purchases of treasury stock	(4)	$ 0	(4)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	155	$ 0	5	150	0	0	0
Stock-based compensation plans and other (in shares)		0
Change in noncontrolling interest	(2)	$ 0	0	0	0	0	(2)
Ending balance at Sep. 30, 2022	$ 16,027	$ 18	$ (4,590)	$ 19,056	$ 4,953	$ (3,443)	$ 33
Ending balance (in shares) at Sep. 30, 2022		1,768

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Cash Flows [Abstract]
Net earnings	$ 9,373	$ 7,504
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	582	630
Amortization of intangible assets	5,728	5,912
Deferred income taxes	(1,415)	(153)
Change in fair value of contingent consideration liabilities	647	2,447
Stock-based compensation	539	563
Acquired IPR&D and milestones	454	719
Other charges related to collaborations	0	500
Gain on divestitures	(172)	(68)
Non-cash litigation reserve adjustments, net of cash payments	2,261	21
Impairment of intangible assets	770	50
Other, net	(151)	(185)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,039)	(572)
Inventories	(516)	(30)
Prepaid expenses and other assets	(60)	(462)
Accounts payable and other liabilities	330	1,454
Income tax assets and liabilities, net	184	(628)
Cash flows from operating activities	17,515	17,702
Cash flows from investing activities
Acquisitions and investments	(494)	(837)
Acquisitions of property and equipment	(482)	(600)
Purchases of investment securities	(1,428)	(73)
Sales and maturities of investment securities	1,460	88
Other, net	769	223
Cash flows from investing activities	(175)	(1,199)
Cash flows from financing activities
Proceeds from issuance of long-term debt	2,000	1,000
Repayments of long-term debt and finance lease obligations	(7,582)	(5,662)
Dividends paid	(7,537)	(6,947)
Purchases of treasury stock	(1,483)	(803)
Proceeds from the exercise of stock options	209	169
Payments of contingent consideration liabilities	(817)	(480)
Other, net	41	22
Cash flows from financing activities	(15,169)	(12,701)
Effect of exchange rate changes on cash and equivalents	(85)	(69)
Net change in cash and equivalents	2,086	3,733
Cash and equivalents, beginning of period	9,746	8,449
Cash and equivalents, end of period	$ 11,832	$ 12,182

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2021. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. During the three months ended March 31, 2022, AbbVie revised its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. Milestone payments incurred prior to regulatory approval, which were previously included in research and development expense, are now presented as acquired IPR&D and milestones expense. The reclassification decreased research and development expense and increased acquired IPR&D and milestones expense by $12 million for the three months and $162 million for the nine months ended September 30, 2021. The company believes this presentation assists users of the financial statements to better understand the total upfront and subsequent development milestone payments incurred to acquire in-process research and development projects. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on total operating costs and expenses, operating earnings, net earnings, net earnings attributable to AbbVie, Inc., earnings per share, or total equity. Certain other reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.

Supplemental Financial Information

9 Months Ended

Sep. 30, 2022

Supplemental Financial Information

Supplemental Financial Information

Supplemental Financial InformationInterest Expense, Net


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Interest expense	$	560	$	596	$	1,664	$	1,843
Interest income	(63)		(11)		(96)		(30)
Interest expense, net	$	497	$	585	$	1,568	$	1,813

Inventories


(in millions)	September 30, 2022		December 31, 2021
Finished goods	$	903	$	932
Work-in-process	1,309		1,193
Raw materials	960		1,003
Inventories	$	3,172	$	3,128

Property and Equipment, Net


(in millions)	September 30, 2022		December 31, 2021
Property and equipment, gross	$	10,679	$	10,727
Accumulated depreciation	(5,786)		(5,617)
Property and equipment, net	$	4,893	$	5,110

Depreciation expense was $181 million for the three months and $582 million for the nine months ended September 30, 2022 and $223 million for the three months and $630 million for the nine months ended September 30, 2021.

Earnings Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:


	Three months ended September 30,				Nine months ended September 30,
(in millions, except per share data)	2022		2021		2022		2021
Basic EPS
Net earnings attributable to AbbVie Inc.	$	3,949	$	3,179	$	9,363	$	7,498
Earnings allocated to participating securities	18		21		43		53
Earnings available to common shareholders	$	3,931	$	3,158	$	9,320	$	7,445
Weighted-average basic shares outstanding	1,771		1,770		1,771		1,769
Basic earnings per share attributable to AbbVie Inc.	$	2.22	$	1.78	$	5.26	$	4.21

Diluted EPS
Net earnings attributable to AbbVie Inc.	$	3,949	$	3,179	$	9,363	$	7,498
Earnings allocated to participating securities	18		21		43		53
Earnings available to common shareholders	$	3,931	$	3,158	$	9,320	$	7,445
Weighted-average shares of common stock outstanding	1,771		1,770		1,771		1,769
Effect of dilutive securities	5		7		6		7
Weighted-average diluted shares outstanding	1,776		1,777		1,777		1,776
Diluted earnings per share attributable to AbbVie Inc.	$	2.21	$	1.78	$	5.24	$	4.19

Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions and Other Arrangements	9 Months Ended
Licensing, Acquisitions and Other Arrangements	Sep. 30, 2022
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Cash outflows related to acquisitions and investments totaled $494 million for the nine months ended September 30, 2022 and $837 million for the nine months ended September 30, 2021. AbbVie recorded acquired IPR&D and milestones expense of $40 million for the three months and $454 million for the nine months ended September 30, 2022 and $402 million for the three months and $719 million for the nine months ended September 30, 2021. Syndesi Therapeutics SA In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule SDI-118 and accounted for the transaction as an asset acquisition. SDI-118 is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded to acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones. Juvise Pharmaceuticals In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the condensed consolidated statement of earnings in the second quarter of 2022. DJS Antibodies Ltd Subsequent to September 30, 2022, AbbVie entered into an agreement to acquire DJS Antibodies Ltd (DJS) including its lead program DJS-002 and proprietary HEPTAD platform. DJS-002 is an LPAR1 antagonist antibody currently in preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases. HEPTAD platform is a potential novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets. Under the terms of the agreement, AbbVie will make an upfront payment of approximately $255 million plus additional future payments of up to $95 million upon achievement of certain development milestones. Calico Life Sciences LLC In July 2021, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second collaboration extension and builds on the partnership established in 2014 and extended in 2018. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million and the term is extended for an additional three years. AbbVie’s contribution is payable in two equal installments beginning in 2023. Calico will be responsible for research and early development until 2025 and will advance collaboration projects into Phase 2a through 2030. Following completion of the Phase 2a studies, AbbVie will have the option to exclusively license the collaboration compounds. Upon exercise, AbbVie would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the third quarter of 2021, AbbVie recorded $500 million as other operating expense in the condensed consolidated statement of earnings related to its commitments under the agreement. TeneoOne and TNB-383B In September 2021, AbbVie acquired TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study and accounted for the transaction as an asset acquisition. Under the terms of the agreement, AbbVie made an exercise payment of $400 million which was recorded to acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the third quarter of 2021. The agreement also included additional payments of up to $250 million upon the achievement of certain development, regulatory and commercial milestones.

Collaborations

9 Months Ended

Sep. 30, 2022

Collaborative Arrangements [Abstract]

Collaborations

The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended September 30, 2022 and 2021.

Collaboration with Janssen Biotech, Inc.

In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton’s tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.

The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.

In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
United States - Janssen's share of profits (included in cost of products sold)	$	398	$	518	$	1,210	$	1,497
International - AbbVie's share of profits (included in net revenues)	286		265		868		816
Global - AbbVie's share of other costs (included in respective line items)	63		76		196		220

AbbVie’s receivable from Janssen, included in accounts receivable, net, was $296 million at September 30, 2022 and $294 million at December 31, 2021. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $379 million at September 30, 2022 and $509 million at December 31, 2021.

Collaboration with Genentech, Inc.

AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States.

AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&A) expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold.

The following table shows the profit and cost sharing relationship between Genentech and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Genentech's share of profits, including royalties (included in cost of products sold)	$	204	$	187	$	578	$	514
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	10		10		27		29
AbbVie's share of development costs (included in R&D)	29		34		87		110

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible AssetsGoodwill

The following table summarizes the changes in the carrying amount of goodwill:


(in millions)
Balance as of December 31, 2021	$	32,379
Foreign currency translation adjustments	(653)
Balance as of September 30, 2022	$	31,726

The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2022, there were no accumulated goodwill impairment losses.

Intangible Assets, Net

The following table summarizes intangible assets:


	September 30, 2022						December 31, 2021
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	87,313	$	(23,368)	$	63,945	$	88,945	$	(18,463)	$	70,482
License agreements	8,486		(4,376)		4,110		8,487		(3,688)		4,799
Total definite-lived intangible assets	95,799		(27,744)		68,055		97,432		(22,151)		75,281
Indefinite-lived intangible assets	670		—		670		670		—		670
Total intangible assets, net	$	96,469	$	(27,744)	$	68,725	$	98,102	$	(22,151)	$	75,951

Definite-Lived Intangible Assets

Amortization expense was $2.0 billion for the three months and $5.7 billion for the nine months ended September 30, 2022 and $1.9 billion for the three months and $5.9 billion for the nine months ended September 30, 2021. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings.

In September 2022, the company made a strategic decision to reduce ongoing sales and marketing investment related to Vuity, an on-market product to treat presbyopia. This strategic decision contributed to a significant decrease in the estimated future cash flows for the product and represented a triggering event which required the company to evaluate the underlying definite lived-intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value of the intangible asset resulting in a full impairment of both the gross and net carrying amount. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $770 million to cost of products sold in the condensed consolidated statement of earnings for the third quarter of 2022.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets represent in-process research and development associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.

Integration and Restructuring Plans

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

Integration and Restructuring Plans

Integration and Restructuring PlansAllergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses.

The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:


	Severance and employee benefits										Other integration
	Three months ended September 30,			Nine months ended September 30,						Three months ended September 30,		Nine months ended September 30,
(in millions)		2022		2021		2022		2021					2022		2021		2022		2021
Cost of products sold		$	—	$	2	$	(4)	$	8				$	24	$	44	$	85	$	84
Research and development		1		—		2		—					3		18		12		87
Selling, general and administrative		4		18		4		47					84		88		230		213
Total charges		$	5	$	20	$	2	$	55				$	111	$	150	$	327	$	384

The following table summarizes the cash activity in the recorded liability associated with the Allergan integration plan for the nine months ended September 30, 2022:


(in millions)	Severance and employee benefits		Other integration
Accrued balance as of December 31, 2021	$	222	$	33
Charges	2		316


Payments and other adjustments	(107)		(343)
Accrued balance as of September 30, 2022	$	117	$	6

Other Restructuring

AbbVie recorded restructuring charges of $50 million for the three months and $143 million for the nine months ended September 30, 2022 and $13 million for the three months and $56 million for the nine months ended September 30, 2021.

The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2022:


(in millions)
Accrued balance as of December 31, 2021	$	33
Restructuring charges	112
Payments and other adjustments	(25)
Accrued balance as of September 30, 2022	$	120

Financial Instruments and Fair Value Measures

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measures

Financial Instruments and Fair Value MeasuresRisk Management Policy

See Note 11 to the company’s Annual Report on Form 10-K for the year ended December 31, 2021 for a summary of AbbVie’s risk management policy and use of derivative instruments.

Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.8 billion at September 30, 2022 and $1.1 billion at December 31, 2021, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of September 30, 2022 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.

In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive loss. This gain is reclassified to interest expense, net over the term of the related debt.

The company is a party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $750 million at September 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt.

The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $6.8 billion at September 30, 2022 and $8.2 billion at December 31, 2021.

The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €4.5 billion at September 30, 2022 and €4.3 billion at December 31, 2021. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of €5.9 billion at September 30, 2022 and December 31, 2021. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.

The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $4.5 billion at September 30, 2022 and December 31, 2021. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:


	Fair value – Derivatives in asset position					Fair value – Derivatives in liability position
(in millions)	Balance sheet caption	September 30, 2022		December 31, 2021		Balance sheet caption	September 30, 2022		December 31, 2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	Prepaid expenses and other	$	153	$	51	Accounts payable and accrued liabilities	$	9	$	2
Designated as cash flow hedges	Other assets	1		—		Other long-term liabilities	—		—
Designated as net investment hedges	Prepaid expenses and other	70		149		Accounts payable and accrued liabilities	—		—
Designated as net investment hedges	Other assets	283		15		Other long-term liabilities	—		—
Not designated as hedges	Prepaid expenses and other	60		26		Accounts payable and accrued liabilities	86		13
Interest rate swap contracts
Designated as cash flow hedges	Prepaid expenses and other	2		—		Accounts payable and accrued liabilities	—		7
Designated as fair value hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	21		—
Designated as fair value hedges	Other assets	—		26		Other long-term liabilities	393		15
Total derivatives		$	569	$	267		$	509	$	37

While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	124	$	43	$	171	$	67
Designated as net investment hedges	362		101		748		186
Interest rate swap contracts designated as cash flow hedges	—		(1)		6		—

Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $150 million into cost of products sold for foreign currency cash flow hedges, pre-tax gains of $2 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months.

Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive loss pre-tax gains of $431 million for three months and pre-tax gains of $932 million for the nine months ended September 30, 2022 and pre-tax gains of $141 million for the three months and pre-tax gains of $397 million for the nine months ended September 30, 2021.

The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI.


		Three months ended September 30,				Nine months ended September 30,
(in millions)	Statement of earnings caption	2022		2021		2022		2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	Cost of products sold	$	21	$	(28)	$	47	$	(62)
Designated as net investment hedges	Interest expense, net	29		7		67		16
Not designated as hedges	Net foreign exchange loss	(121)		(25)		(285)		(53)
Treasury rate lock agreements designated as cash flow hedges	Interest expense, net	6		6		18		18
Interest rate swap contracts
Designated as cash flow hedges	Interest expense, net	—		(6)		(3)		(20)
Designated as fair value hedges	Interest expense, net	(141)		(5)		(424)		(73)
Debt designated as hedged item in fair value hedges	Interest expense, net	141		5		424		73

Fair Value Measures

The fair value hierarchy consists of the following three levels:

•Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;

•Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and

•Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2022:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	11,832	$	4,303	$	7,529	$	—
Money market funds and time deposits	36		—		36		—
Debt securities	31		—		31		—
Equity securities	72		50		22		—
Interest rate swap contracts	2		—		2		—
Foreign currency contracts	567		—		567		—

Total assets	$	12,540	$	4,353	$	8,187	$	—
Liabilities
Interest rate swap contracts	$	414	$	—	$	414	$	—
Foreign currency contracts	95		—		95		—

Contingent consideration	14,556		—		—		14,556
Total liabilities	$	15,065	$	—	$	509	$	14,556

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	9,746	$	4,451	$	5,295	$	—
Money market funds and time deposits	45		—		45		—
Debt securities	46		—		46		—
Equity securities	121		100		21		—
Interest rate swap contracts	26		—		26		—
Foreign currency contracts	241		—		241		—

Total assets	$	10,225	$	4,551	$	5,674	$	—
Liabilities
Interest rate swap contracts	$	22	$	—	$	22	$	—
Foreign currency contracts	15		—		15		—

Contingent consideration	14,887		—		—		14,887
Total liabilities	$	14,924	$	—	$	37	$	14,887

Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies.

The fair value measurements of contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, probabilities of

achieving the milestones, time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period.

The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:


	September 30, 2022		December 31, 2021
(in millions)	Range	Weighted average(a)	Range	Weighted average(a)
Discount rate	4.1% - 5.5%	5.0%	0.2%- 2.6%	1.7%
Probability of payment for unachieved milestones	89% - 100%	91%	89% - 100%	90%
Probability of payment for royalties by indication(b)	56% - 100%	98%	56% - 100%	96%

Projected year of payments	2022 - 2034	2027	2022 - 2034	2027

(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at September 30, 2022 and December 31, 2021.

There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:


	Nine months ended September 30,
(in millions)	2022		2021
Beginning balance	$	14,887	$	12,997
Change in fair value recognized in net earnings	647		2,447
Payments	(978)		(525)
Ending balance	$	14,556	$	14,919

The change in fair value recognized in net earnings is recorded in other expense (income), net in the condensed consolidated statements of earnings.

Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2022 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	10	$	10	$	—	$	10	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,215		9,191		9,071		120		—
Long-term debt and finance lease obligations, excluding fair value hedges	60,740		53,834		53,093		741		—
Total liabilities	$	69,965	$	63,035	$	62,164	$	871	$	—

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	14	$	14	$	—	$	14	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	12,455		11,830		11,329		501		—
Long-term debt and finance lease obligations, excluding fair value hedges	64,113		71,810		70,757		1,053		—
Total liabilities	$	76,582	$	83,654	$	82,086	$	1,568	$	—

AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $143 million as of September 30, 2022 and $149 million as of December 31, 2021. No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2022.

Concentrations of Risk

Of total net accounts receivable, three U.S. wholesalers accounted for 79% as of September 30, 2022 and 75% as of December 31, 2021, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to these three wholesalers.

Humira (adalimumab) is AbbVie’s single largest product and accounted for approximately 36% of AbbVie’s total net revenues for the nine months ended September 30, 2022 and 37% for the nine months ended September 30, 2021.

Debt and Credit Facilities

In January 2022, the company repaid $2.9 billion aggregate principal amount of 3.45% senior notes that were scheduled to mature in March 2022. This repayment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.

In February 2022, the company refinanced its $2.0 billion floating rate five-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.

In July 2022, the company repaid $1.7 billion aggregate principal amount of 3.25% senior notes that were scheduled to mature in October 2022. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.

In September 2022, the company repaid $1.0 billion aggregate principal amount of 3.2% senior notes that were scheduled to mature in November 2022. This payment was made by exercising, under the terms of the notes, 60-day early redemption at 100% of the principal amount.

In April 2021, the company repaid $1.8 billion aggregate principal amount of 2.3% senior notes that were scheduled to mature in May 2021. In May 2021, the company repaid €750 million aggregate principal amount of 0.5% senior euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in May 2021.

In September 2021, the company refinanced its $1.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $1.0 billion term loan due May 2023 and borrowed $1.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing.

In September 2021, the company repaid $1.2 billion aggregate principal amount of 5.0% senior notes that were scheduled to mature in December 2021. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount.

Post-Employment Benefits

9 Months Ended

Sep. 30, 2022

Postemployment Benefits [Abstract]

Post-Employment Benefits

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:


	Defined benefit plans								Other post- employment plans
	Three months ended September 30,				Nine months ended September 30,				Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021		2022		2021		2022		2021
Service cost	$	113	$	110	$	342	$	331	$	13	$	12	$	38	$	36
Interest cost	74		59		223		177		6		5		18		14
Expected return on plan assets	(177)		(166)		(536)		(498)		—		—		—		—
Amortization of prior service cost (credit)	1		1		2		2		(10)		(10)		(29)		(29)
Amortization of actuarial loss	57		72		173		217		7		8		20		24
Net periodic benefit cost	$	68	$	76	$	204	$	229	$	16	$	15	$	47	$	45

The components of net periodic benefit cost other than service cost are included in other expense (income), net in the condensed consolidated statements of earnings.

Equity

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Equity

EquityStock-Based Compensation

In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Cost of products sold	$	8	$	9	$	33	$	39
Research and development	47		47		194		181
Selling, general and administrative	71		79		312		343
Pre-tax compensation expense	126		135		539		563
Tax benefit	25		27		102		101
After-tax compensation expense	$	101	$	108	$	437	$	462

Stock Options

During the nine months ended September 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 0.9 million stock options with a weighted-average grant-date fair value of $22.83. As of September 30, 2022, $8 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

RSUs and Performance Shares

During the nine months ended September 30, 2022, primarily in connection with the company's annual grant, AbbVie granted 5.9 million RSUs and performance shares with a weighted-average grant-date fair value of $146.30. As of September 30, 2022, $692 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.

Cash Dividends

The following table summarizes quarterly cash dividends declared during 2022 and 2021:


2022				2021
Date Declared	Payment Date	Dividend Per Share		Date Declared	Payment Date	Dividend Per Share
10/28/22	02/15/23	$	1.48	10/29/21	02/15/22	$	1.41
09/09/22	11/15/22	$	1.41	09/10/21	11/15/21	$	1.30
06/23/22	08/15/22	$	1.41	06/17/21	08/16/21	$	1.30
02/17/22	05/16/22	$	1.41	02/18/21	05/14/21	$	1.30

Stock Repurchase Program

The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.

AbbVie repurchased 8 million shares for $1.1 billion during the nine months ended September 30, 2022 and 5 million shares for $550 million during the nine months ended September 30, 2021. AbbVie's remaining stock repurchase authorization was approximately $1.4 billion as of September 30, 2022.

Accumulated Other Comprehensive Loss

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2022:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2021	$	(570)	$	(91)	$	(2,546)	$	308	$	(2,899)
Other comprehensive income (loss) before reclassifications	(2,043)		1,318		6		151		(568)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(53)		130		(53)		24
Net current-period other comprehensive income (loss)	(2,043)		1,265		136		98		(544)
Balance as of September 30, 2022	$	(2,613)	$	1,174	$	(2,410)	$	406	$	(3,443)

Other comprehensive loss for the nine months ended September 30, 2022 included foreign currency translation adjustments totaling a loss of $2.0 billion and the offsetting impact of net investment hedging activities totaling a gain of $1.3 billion, which were principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets.

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2021:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2020	$	583	$	(790)	$	(3,067)	$	157	$	(3,117)
Other comprehensive income (loss) before reclassifications	(794)		457		27		60		(250)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(13)		169		55		211
Net current-period other comprehensive income (loss)	(794)		444		196		115		(39)
Balance as of September 30, 2021	$	(211)	$	(346)	$	(2,871)	$	272	$	(3,156)

Other comprehensive loss for the nine months ended September 30, 2021 included foreign currency translation adjustments totaling a loss of $794 million and the offsetting impact of net investment hedging activities totaling a gain of $444 million, which were principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets.

The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions) (brackets denote gains)	2022		2021		2022		2021
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)	$	(29)	$	(7)	$	(67)	$	(16)
Tax expense	6		1		14		3
Total reclassifications, net of tax	$	(23)	$	(6)	$	(53)	$	(13)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)	$	55	$	71	$	166	$	214
Tax benefit	(12)		(15)		(36)		(45)
Total reclassifications, net of tax	$	43	$	56	$	130	$	169
Cash flow hedging activities
Losses (gains) on foreign currency forward exchange contracts(c)	$	(21)	$	28	$	(47)	$	62
Gains on treasury rate lock agreements(a)	(6)		(6)		(18)		(18)
Losses on interest rate swap contracts(a)	—		6		3		20
Tax expense (benefit)	4		(4)		9		(9)
Total reclassifications, net of tax	$	(23)	$	24	$	(53)	$	55

(a) Amounts are included in interest expense, net (see Note 8).

(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 10% for the three months and 11% for the nine months ended September 30, 2022 compared to 14% for the three and nine months ended September 30, 2021. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the impact of foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions, business development activities and accretion on contingent consideration. The decrease in the effective tax rate for the three and nine months ended September 30, 2022 over the prior year was primarily due to differences in the company’s jurisdictional mix of earnings, accretion on contingent consideration, and acquired IPR&D and milestones.Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next 12 months by up to $141 million.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Legal Proceedings and Contingencies	9 Months Ended
Legal Proceedings and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motion to certify a class. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also alleging that 2011 patent litigation by Abbott with two generic companies regarding AndroGel was sham litigation and the settlements of those litigations violated federal antitrust law. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others, alleging that Abbott’s 2011 AndroGel patent lawsuit filed against Perrigo was sham litigation. In September 2021, the United States District Court for the District of New Jersey granted AbbVie's motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. The United States Court of Appeals for the Third Circuit affirmed that dismissal in July 2022 and denied Perrigo’s petition for rehearing in August 2022. Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as In re: Humira (Adalimumab) Antitrust Litigation. In June 2020, the court dismissed the consolidated litigation with prejudice. In August 2022, the United States Court of Appeals for the Seventh Circuit affirmed that dismissal. Lawsuits are pending against Forest Laboratories, LLC, an AbbVie subsidiary, and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as In re: Namenda Indirect Purchaser Antitrust Litigation in the United States District Court for the Southern District of New York. In October 2022, the parties reached an agreement in principle to settle this matter. Lawsuits are pending against Allergan Inc., an Allergan subsidiary, generally alleging that Allergan’s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In August 2022, the court granted final approval to the parties’ agreement to settle this matter. Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 3,083 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 284 matters are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. Allergan has previously reached settlements with certain states, counties, and cities. Allergan is engaged in negotiations with representatives for the remaining states, counties, cities, other municipal entities and Native American tribes regarding a potential settlement, with payments likely to be made over a number of years. While negotiations are on-going and definitive terms have not been reached, a framework for an agreement exists, including an estimate of a potential settlement amount based on maximum participation in the potential settlement. AbbVie recorded a charge of $2.1 billion to selling, general and administrative expense in the consolidated statement of earnings in the second quarter of 2022 related to this potential settlement. In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al., in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico’s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. In August 2022, the parties finalized their settlement of this matter. Shareholder and Securities Litigation In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. One appeal was dismissed with prejudice in August 2021. In the other two appeals, the Illinois Appellate Court affirmed the dismissal of one in March 2021 and affirmed the dismissal of the other in February 2022. One of these plaintiffs refiled its lawsuit in the New York Supreme Court for the County of New York, where it was dismissed in November 2020, and that dismissal was affirmed by the Supreme Court of New York, Appellate Division, in January 2022. In September 2021, the Illinois court granted AbbVie's motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. Those plaintiffs have appealed the dismissals. In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May 2022, a shareholder derivative lawsuit, Ranney v. Gonzalez, et al., was filed in Delaware Chancery Court, alleging that certain AbbVie directors and officers breached their fiduciary duties based on related allegations. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2021, the court granted plaintiffs' motion to certify a class. In April 2022, a federal securities lawsuit, Nakata v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois against AbbVie and certain officers alleging misstatements regarding the potential effect that safety information about another company’s product would have on the Food and Drug Administration’s approval and labeling for AbbVie’s Rinvoq. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the same court, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties based on related allegations. Product Liability and General Litigation In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In August 2022, the United States Court of Appeals reversed the district court’s denial of Allergan’s motion to dismiss the case. Intellectual Property Litigation Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd.. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. An appellate hearing occurred in October 2022. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits. AbbVie Inc. is seeking to enforce patent rights relating to venetoclax (a drug sold under the trademark Venclexta). Litigation was filed in the United States District Court for the District of Delaware in July 2020 against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc.: and Alembic Pharmaceuticals Ltd., Alembic Pharmaceuticals, Inc., and Alembic Global Holdings SA. AbbVie alleges defendants’ proposed generic venetoclax products infringe certain patents and seeks declaratory and injunctive relief. Genentech, Inc., which is in a global collaboration with AbbVie concerning the development and marketing of Venclexta, is the co-plaintiff in this suit.

Segment Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Segment Information

Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.The following table details AbbVie’s worldwide net revenues:


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2022		2021		2022		2021
Immunology
Humira	United States	$	4,956	$	4,613	$	13,613	$	12,777
	International	603		812		2,045		2,583
	Total	$	5,559	$	5,425	$	15,658	$	15,360
Skyrizi	United States	$	1,221	$	679	$	3,081	$	1,725
	International	176		117		508		319
	Total	$	1,397	$	796	$	3,589	$	2,044
Rinvoq	United States	$	505	$	348	$	1,228	$	889
	International	190		105		524		245
	Total	$	695	$	453	$	1,752	$	1,134
Hematologic Oncology
Imbruvica	United States	$	849	$	1,109	$	2,585	$	3,207
	Collaboration revenues	286		265		868		816
	Total	$	1,135	$	1,374	$	3,453	$	4,023
Venclexta	United States	$	259	$	237	$	740	$	685
	International	256		255		753		647
	Total	$	515	$	492	$	1,493	$	1,332
Aesthetics
Botox Cosmetic	United States	$	370	$	356	$	1,232	$	1,027
	International	267		189		741		579
	Total	$	637	$	545	$	1,973	$	1,606
Juvederm Collection	United States	$	125	$	159	$	420	$	478
	International	227		195		686		625
	Total	$	352	$	354	$	1,106	$	1,103
Other Aesthetics	United States	$	265	$	305	$	837	$	968
	International	47		47		130		149
	Total	$	312	$	352	$	967	$	1,117
Neuroscience
Botox Therapeutic	United States	$	584	$	534	$	1,641	$	1,451
	International	115		111		350		329
	Total	$	699	$	645	$	1,991	$	1,780
Vraylar	United States	$	554	$	461	$	1,473	$	1,239


Duodopa	United States	$	22	$	23	$	72	$	73
	International	88		104		279		310
	Total	$	110	$	127	$	351	$	383
Ubrelvy	United States	$	160	$	162	$	483	$	369


Qulipta	United States	$	62	$	—	$	106	$	—
Other Neuroscience	United States	$	82	$	166	$	400	$	489
	International	5		5		14		13
	Total	$	87	$	171	$	414	$	502


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2022		2021		2022		2021
Eye Care
Lumigan/Ganfort	United States	$	59	$	63	$	186	$	201
	International	62		75		205		229
	Total	$	121	$	138	$	391	$	430
Alphagan/Combigan	United States	$	37	$	89	$	161	$	271
	International	36		39		111		117
	Total	$	73	$	128	$	272	$	388
Restasis	United States	$	132	$	305	$	518	$	884
	International	10		14		38		42
	Total	$	142	$	319	$	556	$	926
Other Eye Care	United States	$	134	$	128	$	400	$	375
	International	153		158		492		488
	Total	$	287	$	286	$	892	$	863
Other Key Products
Mavyret	United States	$	190	$	183	$	562	$	557
	International	193		243		599		726
	Total	$	383	$	426	$	1,161	$	1,283
Creon	United States	$	336	$	310	$	941	$	864
Linzess/Constella	United States	$	262	$	253	$	742	$	728
	International	9		8		24		23
	Total	$	271	$	261	$	766	$	751



All other		$	925	$	1,117	$	3,145	$	3,814
Total net revenues		$	14,812	$	14,342	$	42,933	$	41,311

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Supplemental Financial Information (Tables)

9 Months Ended

Sep. 30, 2022

Supplemental Financial Information

Schedule of interest expense, net

Interest Expense, Net


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Interest expense	$	560	$	596	$	1,664	$	1,843
Interest income	(63)		(11)		(96)		(30)
Interest expense, net	$	497	$	585	$	1,568	$	1,813

Schedule of inventories

Inventories


(in millions)	September 30, 2022		December 31, 2021
Finished goods	$	903	$	932
Work-in-process	1,309		1,193
Raw materials	960		1,003
Inventories	$	3,172	$	3,128

Schedule of property and equipment, net

Property and Equipment, Net


(in millions)	September 30, 2022		December 31, 2021
Property and equipment, gross	$	10,679	$	10,727
Accumulated depreciation	(5,786)		(5,617)
Property and equipment, net	$	4,893	$	5,110

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of basic and diluted earnings per share, impact of two-class method

The following table summarizes the impact of the two-class method:


	Three months ended September 30,				Nine months ended September 30,
(in millions, except per share data)	2022		2021		2022		2021
Basic EPS
Net earnings attributable to AbbVie Inc.	$	3,949	$	3,179	$	9,363	$	7,498
Earnings allocated to participating securities	18		21		43		53
Earnings available to common shareholders	$	3,931	$	3,158	$	9,320	$	7,445
Weighted-average basic shares outstanding	1,771		1,770		1,771		1,769
Basic earnings per share attributable to AbbVie Inc.	$	2.22	$	1.78	$	5.26	$	4.21

Diluted EPS
Net earnings attributable to AbbVie Inc.	$	3,949	$	3,179	$	9,363	$	7,498
Earnings allocated to participating securities	18		21		43		53
Earnings available to common shareholders	$	3,931	$	3,158	$	9,320	$	7,445
Weighted-average shares of common stock outstanding	1,771		1,770		1,771		1,769
Effect of dilutive securities	5		7		6		7
Weighted-average diluted shares outstanding	1,776		1,777		1,777		1,776
Diluted earnings per share attributable to AbbVie Inc.	$	2.21	$	1.78	$	5.24	$	4.19

Collaborations (Tables)

9 Months Ended

Sep. 30, 2022

Janssen Biotech Inc.

Collaborative and license agreements

Schedule of profit and cost sharing relationship

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
United States - Janssen's share of profits (included in cost of products sold)	$	398	$	518	$	1,210	$	1,497
International - AbbVie's share of profits (included in net revenues)	286		265		868		816
Global - AbbVie's share of other costs (included in respective line items)	63		76		196		220

Genentech, Inc.

Collaborative and license agreements

Schedule of profit and cost sharing relationship

The following table shows the profit and cost sharing relationship between Genentech and AbbVie:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Genentech's share of profits, including royalties (included in cost of products sold)	$	204	$	187	$	578	$	514
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	10		10		27		29
AbbVie's share of development costs (included in R&D)	29		34		87		110

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of changes in the carrying amount of goodwill

The following table summarizes the changes in the carrying amount of goodwill:


(in millions)
Balance as of December 31, 2021	$	32,379
Foreign currency translation adjustments	(653)
Balance as of September 30, 2022	$	31,726

Summary of definite-lived intangible assets

The following table summarizes intangible assets:


	September 30, 2022						December 31, 2021
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	87,313	$	(23,368)	$	63,945	$	88,945	$	(18,463)	$	70,482
License agreements	8,486		(4,376)		4,110		8,487		(3,688)		4,799
Total definite-lived intangible assets	95,799		(27,744)		68,055		97,432		(22,151)		75,281
Indefinite-lived intangible assets	670		—		670		670		—		670
Total intangible assets, net	$	96,469	$	(27,744)	$	68,725	$	98,102	$	(22,151)	$	75,951

Summary of indefinite-lived intangible assets

The following table summarizes intangible assets:


	September 30, 2022						December 31, 2021
(in millions)	Gross carrying amount		Accumulated amortization		Net carrying amount		Gross carrying amount		Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$	87,313	$	(23,368)	$	63,945	$	88,945	$	(18,463)	$	70,482
License agreements	8,486		(4,376)		4,110		8,487		(3,688)		4,799
Total definite-lived intangible assets	95,799		(27,744)		68,055		97,432		(22,151)		75,281
Indefinite-lived intangible assets	670		—		670		670		—		670
Total intangible assets, net	$	96,469	$	(27,744)	$	68,725	$	98,102	$	(22,151)	$	75,951

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Integration and Restructuring Plans (Tables)

9 Months Ended

Sep. 30, 2022

Allergan integration plan

Restructuring charges

Summary of charges associated with integration plan

The following table summarizes the charges (benefits) associated with the Allergan acquisition integration plan:


	Severance and employee benefits										Other integration
	Three months ended September 30,			Nine months ended September 30,						Three months ended September 30,		Nine months ended September 30,
(in millions)		2022		2021		2022		2021					2022		2021		2022		2021
Cost of products sold		$	—	$	2	$	(4)	$	8				$	24	$	44	$	85	$	84
Research and development		1		—		2		—					3		18		12		87
Selling, general and administrative		4		18		4		47					84		88		230		213
Total charges		$	5	$	20	$	2	$	55				$	111	$	150	$	327	$	384

Summary of cash activity in the restructuring reserve

The following table summarizes the cash activity in the recorded liability associated with the Allergan integration plan for the nine months ended September 30, 2022:


(in millions)	Severance and employee benefits		Other integration
Accrued balance as of December 31, 2021	$	222	$	33
Charges	2		316


Payments and other adjustments	(107)		(343)
Accrued balance as of September 30, 2022	$	117	$	6

Other restructuring

Restructuring charges

Summary of cash activity in the restructuring reserve

The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2022:


(in millions)
Accrued balance as of December 31, 2021	$	33
Restructuring charges	112
Payments and other adjustments	(25)
Accrued balance as of September 30, 2022	$	120

Financial Instruments and Fair Value Measures (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Summary of amounts and location of derivatives on the condensed consolidated balance sheets

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:


	Fair value – Derivatives in asset position					Fair value – Derivatives in liability position
(in millions)	Balance sheet caption	September 30, 2022		December 31, 2021		Balance sheet caption	September 30, 2022		December 31, 2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	Prepaid expenses and other	$	153	$	51	Accounts payable and accrued liabilities	$	9	$	2
Designated as cash flow hedges	Other assets	1		—		Other long-term liabilities	—		—
Designated as net investment hedges	Prepaid expenses and other	70		149		Accounts payable and accrued liabilities	—		—
Designated as net investment hedges	Other assets	283		15		Other long-term liabilities	—		—
Not designated as hedges	Prepaid expenses and other	60		26		Accounts payable and accrued liabilities	86		13
Interest rate swap contracts
Designated as cash flow hedges	Prepaid expenses and other	2		—		Accounts payable and accrued liabilities	—		7
Designated as fair value hedges	Prepaid expenses and other	—		—		Accounts payable and accrued liabilities	21		—
Designated as fair value hedges	Other assets	—		26		Other long-term liabilities	393		15
Total derivatives		$	569	$	267		$	509	$	37

Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	124	$	43	$	171	$	67
Designated as net investment hedges	362		101		748		186
Interest rate swap contracts designated as cash flow hedges	—		(1)		6		—

Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	$	124	$	43	$	171	$	67
Designated as net investment hedges	362		101		748		186
Interest rate swap contracts designated as cash flow hedges	—		(1)		6		—

Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings


		Three months ended September 30,				Nine months ended September 30,
(in millions)	Statement of earnings caption	2022		2021		2022		2021
Foreign currency forward exchange contracts
Designated as cash flow hedges	Cost of products sold	$	21	$	(28)	$	47	$	(62)
Designated as net investment hedges	Interest expense, net	29		7		67		16
Not designated as hedges	Net foreign exchange loss	(121)		(25)		(285)		(53)
Treasury rate lock agreements designated as cash flow hedges	Interest expense, net	6		6		18		18
Interest rate swap contracts
Designated as cash flow hedges	Interest expense, net	—		(6)		(3)		(20)
Designated as fair value hedges	Interest expense, net	(141)		(5)		(424)		(73)
Debt designated as hedged item in fair value hedges	Interest expense, net	141		5		424		73

Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	11,832	$	4,303	$	7,529	$	—
Money market funds and time deposits	36		—		36		—
Debt securities	31		—		31		—
Equity securities	72		50		22		—
Interest rate swap contracts	2		—		2		—
Foreign currency contracts	567		—		567		—

Total assets	$	12,540	$	4,353	$	8,187	$	—
Liabilities
Interest rate swap contracts	$	414	$	—	$	414	$	—
Foreign currency contracts	95		—		95		—

Contingent consideration	14,556		—		—		14,556
Total liabilities	$	15,065	$	—	$	509	$	14,556

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2021:


			Basis of fair value measurement
(in millions)	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$	9,746	$	4,451	$	5,295	$	—
Money market funds and time deposits	45		—		45		—
Debt securities	46		—		46		—
Equity securities	121		100		21		—
Interest rate swap contracts	26		—		26		—
Foreign currency contracts	241		—		241		—

Total assets	$	10,225	$	4,551	$	5,674	$	—
Liabilities
Interest rate swap contracts	$	22	$	—	$	22	$	—
Foreign currency contracts	15		—		15		—

Contingent consideration	14,887		—		—		14,887
Total liabilities	$	14,924	$	—	$	37	$	14,887

Summary of significant level 3 unobservable inputs

The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs:


	September 30, 2022		December 31, 2021
(in millions)	Range	Weighted average(a)	Range	Weighted average(a)
Discount rate	4.1% - 5.5%	5.0%	0.2%- 2.6%	1.7%
Probability of payment for unachieved milestones	89% - 100%	91%	89% - 100%	90%
Probability of payment for royalties by indication(b)	56% - 100%	98%	56% - 100%	96%

Projected year of payments	2022 - 2034	2027	2022 - 2034	2027

(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at September 30, 2022 and December 31, 2021.

Schedule of changes in fair value of Level 3 inputs

The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs:


	Nine months ended September 30,
(in millions)	2022		2021
Beginning balance	$	14,887	$	12,997
Change in fair value recognized in net earnings	647		2,447
Payments	(978)		(525)
Ending balance	$	14,556	$	14,919

Schedule of book values, approximate fair values and bases used to measure certain financial instruments

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2022 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	10	$	10	$	—	$	10	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,215		9,191		9,071		120		—
Long-term debt and finance lease obligations, excluding fair value hedges	60,740		53,834		53,093		741		—
Total liabilities	$	69,965	$	63,035	$	62,164	$	871	$	—

The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2021 are shown in the table below:


					Basis of fair value measurement
(in millions)	Book value		Approximate fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)



Liabilities
Short-term borrowings	$	14	$	14	$	—	$	14	$	—
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	12,455		11,830		11,329		501		—
Long-term debt and finance lease obligations, excluding fair value hedges	64,113		71,810		70,757		1,053		—
Total liabilities	$	76,582	$	83,654	$	82,086	$	1,568	$	—

Post-Employment Benefits (Tables)

9 Months Ended

Sep. 30, 2022

Postemployment Benefits [Abstract]

Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:


	Defined benefit plans								Other post- employment plans
	Three months ended September 30,				Nine months ended September 30,				Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021		2022		2021		2022		2021
Service cost	$	113	$	110	$	342	$	331	$	13	$	12	$	38	$	36
Interest cost	74		59		223		177		6		5		18		14
Expected return on plan assets	(177)		(166)		(536)		(498)		—		—		—		—
Amortization of prior service cost (credit)	1		1		2		2		(10)		(10)		(29)		(29)
Amortization of actuarial loss	57		72		173		217		7		8		20		24
Net periodic benefit cost	$	68	$	76	$	204	$	229	$	16	$	15	$	47	$	45

Equity (Tables)

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Summary of share-based compensation expense

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows:


	Three months ended September 30,				Nine months ended September 30,
(in millions)	2022		2021		2022		2021
Cost of products sold	$	8	$	9	$	33	$	39
Research and development	47		47		194		181
Selling, general and administrative	71		79		312		343
Pre-tax compensation expense	126		135		539		563
Tax benefit	25		27		102		101
After-tax compensation expense	$	101	$	108	$	437	$	462

Summary of quarterly cash dividends

The following table summarizes quarterly cash dividends declared during 2022 and 2021:


2022				2021
Date Declared	Payment Date	Dividend Per Share		Date Declared	Payment Date	Dividend Per Share
10/28/22	02/15/23	$	1.48	10/29/21	02/15/22	$	1.41
09/09/22	11/15/22	$	1.41	09/10/21	11/15/21	$	1.30
06/23/22	08/15/22	$	1.41	06/17/21	08/16/21	$	1.30
02/17/22	05/16/22	$	1.41	02/18/21	05/14/21	$	1.30

Summary of changes in balances of each component of accumulated other comprehensive loss

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2022:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2021	$	(570)	$	(91)	$	(2,546)	$	308	$	(2,899)
Other comprehensive income (loss) before reclassifications	(2,043)		1,318		6		151		(568)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(53)		130		(53)		24
Net current-period other comprehensive income (loss)	(2,043)		1,265		136		98		(544)
Balance as of September 30, 2022	$	(2,613)	$	1,174	$	(2,410)	$	406	$	(3,443)

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2021:


(in millions)	Foreign currency translation adjustments		Net investment hedging activities		Pension and post-employment benefits		Cash flow hedging activities		Total
Balance as of December 31, 2020	$	583	$	(790)	$	(3,067)	$	157	$	(3,117)
Other comprehensive income (loss) before reclassifications	(794)		457		27		60		(250)
Net losses (gains) reclassified from accumulated other comprehensive loss	—		(13)		169		55		211
Net current-period other comprehensive income (loss)	(794)		444		196		115		(39)
Balance as of September 30, 2021	$	(211)	$	(346)	$	(2,871)	$	272	$	(3,156)

Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss

The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:


	Three months ended September 30,				Nine months ended September 30,
(in millions) (brackets denote gains)	2022		2021		2022		2021
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)	$	(29)	$	(7)	$	(67)	$	(16)
Tax expense	6		1		14		3
Total reclassifications, net of tax	$	(23)	$	(6)	$	(53)	$	(13)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)	$	55	$	71	$	166	$	214
Tax benefit	(12)		(15)		(36)		(45)
Total reclassifications, net of tax	$	43	$	56	$	130	$	169
Cash flow hedging activities
Losses (gains) on foreign currency forward exchange contracts(c)	$	(21)	$	28	$	(47)	$	62
Gains on treasury rate lock agreements(a)	(6)		(6)		(18)		(18)
Losses on interest rate swap contracts(a)	—		6		3		20
Tax expense (benefit)	4		(4)		9		(9)
Total reclassifications, net of tax	$	(23)	$	24	$	(53)	$	55

(a) Amounts are included in interest expense, net (see Note 8).

(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).

Segment Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of worldwide net revenues

The following table details AbbVie’s worldwide net revenues:


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2022		2021		2022		2021
Immunology
Humira	United States	$	4,956	$	4,613	$	13,613	$	12,777
	International	603		812		2,045		2,583
	Total	$	5,559	$	5,425	$	15,658	$	15,360
Skyrizi	United States	$	1,221	$	679	$	3,081	$	1,725
	International	176		117		508		319
	Total	$	1,397	$	796	$	3,589	$	2,044
Rinvoq	United States	$	505	$	348	$	1,228	$	889
	International	190		105		524		245
	Total	$	695	$	453	$	1,752	$	1,134
Hematologic Oncology
Imbruvica	United States	$	849	$	1,109	$	2,585	$	3,207
	Collaboration revenues	286		265		868		816
	Total	$	1,135	$	1,374	$	3,453	$	4,023
Venclexta	United States	$	259	$	237	$	740	$	685
	International	256		255		753		647
	Total	$	515	$	492	$	1,493	$	1,332
Aesthetics
Botox Cosmetic	United States	$	370	$	356	$	1,232	$	1,027
	International	267		189		741		579
	Total	$	637	$	545	$	1,973	$	1,606
Juvederm Collection	United States	$	125	$	159	$	420	$	478
	International	227		195		686		625
	Total	$	352	$	354	$	1,106	$	1,103
Other Aesthetics	United States	$	265	$	305	$	837	$	968
	International	47		47		130		149
	Total	$	312	$	352	$	967	$	1,117
Neuroscience
Botox Therapeutic	United States	$	584	$	534	$	1,641	$	1,451
	International	115		111		350		329
	Total	$	699	$	645	$	1,991	$	1,780
Vraylar	United States	$	554	$	461	$	1,473	$	1,239


Duodopa	United States	$	22	$	23	$	72	$	73
	International	88		104		279		310
	Total	$	110	$	127	$	351	$	383
Ubrelvy	United States	$	160	$	162	$	483	$	369


Qulipta	United States	$	62	$	—	$	106	$	—
Other Neuroscience	United States	$	82	$	166	$	400	$	489
	International	5		5		14		13
	Total	$	87	$	171	$	414	$	502


		Three months ended September 30,				Nine months ended September 30,

(in millions)		2022		2021		2022		2021
Eye Care
Lumigan/Ganfort	United States	$	59	$	63	$	186	$	201
	International	62		75		205		229
	Total	$	121	$	138	$	391	$	430
Alphagan/Combigan	United States	$	37	$	89	$	161	$	271
	International	36		39		111		117
	Total	$	73	$	128	$	272	$	388
Restasis	United States	$	132	$	305	$	518	$	884
	International	10		14		38		42
	Total	$	142	$	319	$	556	$	926
Other Eye Care	United States	$	134	$	128	$	400	$	375
	International	153		158		492		488
	Total	$	287	$	286	$	892	$	863
Other Key Products
Mavyret	United States	$	190	$	183	$	562	$	557
	International	193		243		599		726
	Total	$	383	$	426	$	1,161	$	1,283
Creon	United States	$	336	$	310	$	941	$	864
Linzess/Constella	United States	$	262	$	253	$	742	$	728
	International	9		8		24		23
	Total	$	271	$	261	$	766	$	751



All other		$	925	$	1,117	$	3,145	$	3,814
Total net revenues		$	14,812	$	14,342	$	42,933	$	41,311

Basis of Presentation (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
Basis of Presentation (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassification of development milestone expense to IPR&D and milestones expense	$ 12	$ 162
Reclassification of development milestone expense from research and development expense	$ 12	$ 162

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Interest Expense, Net
Interest expense	$ 560	$ 596	$ 1,664	$ 1,843
Interest income	(63)	(11)	(96)	(30)
Interest expense, net	497	585	1,568	1,813
Inventories
Finished goods	903		903		$ 932
Work-in-process	1,309		1,309		1,193
Raw materials	960		960		1,003
Inventories	3,172		3,172		3,128
Property and Equipment
Property and equipment, gross	10,679		10,679		10,727
Accumulated depreciation	(5,786)		(5,786)		(5,617)
Property and equipment, net	4,893		4,893		$ 5,110
Depreciation expense	$ 181	$ 223	$ 582	$ 630

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 3,949	$ 3,179	$ 9,363	$ 7,498
Earnings allocated to participating securities	18	21	43	53
Earnings available to common shareholders	$ 3,931	$ 3,158	$ 9,320	$ 7,445
Weighted-average basic shares outstanding (in shares)	1,771	1,770	1,771	1,769
Basic earnings per share (in dollars per share)	$ 2.22	$ 1.78	$ 5.26	$ 4.21
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 3,949	$ 3,179	$ 9,363	$ 7,498
Earnings allocated to participating securities	18	21	43	53
Earnings available to common shareholders	$ 3,931	$ 3,158	$ 9,320	$ 7,445
Weighted-average basic shares outstanding (in shares)	1,771	1,770	1,771	1,769
Effect of dilutive securities (in shares)	5	7	6	7
Weighted-average diluted shares outstanding (in shares)	1,776	1,777	1,777	1,776
Diluted earnings per share (in dollars per share)	$ 2.21	$ 1.78	$ 5.24	$ 4.19

Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended				9 Months Ended
	Nov. 04, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Feb. 28, 2022
Collaborative and license agreements
Cash outflows related to acquisitions and investments						$ (494)	$ (837)
Acquired IPR&D and milestones		$ 40			$ 402	454	719
Pre-tax gain recognized on sale of assets						172	68
Additional Contribution to Collaboration By Partner					500
Other operating expense, net		$ (229)			(500)	$ (57)	(432)
Forecast \| DJS Antibodies Ltd \| Subsequent event
Collaborative and license agreements
Total consideration	$ 255
Syndesi \| Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones				$ 130
Syndesi \| Collaborative arrangement \| Maximum
Collaborative and license agreements
Potential payments under agreement certain milestones								$ 870
Juvise Pharmaceuticals
Collaborative and license agreements
Proceeds from sale of assets			$ 215
Juvise Pharmaceuticals \| Other operating income (expense)
Collaborative and license agreements
Pre-tax gain recognized on sale of assets			$ 172
DJS Antibodies Ltd \| Maximum \| Subsequent event
Collaborative and license agreements
Potential payments under agreement certain milestones	$ 95
Calico Life Sciences LLC \| Collaborative arrangement
Collaborative and license agreements
Additional Contribution to Collaboration					500
Other operating expense, net					500
TeneoOne \| Collaborative arrangement
Collaborative and license agreements
Acquired IPR&D and milestones					400
TeneoOne \| Collaborative arrangement \| Maximum
Collaborative and license agreements
Potential payments under agreement certain milestones					$ 250		$ 250

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Collaborations (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative and license agreements
AbbVie's receivable from Janssen	$ 10,743		$ 10,743		$ 9,977
AbbVie's payable to Janssen	23,505		23,505		22,699
Janssen Biotech Inc. \| Collaborative arrangement
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	63	$ 76	$ 196	$ 220
AbbVie's receivable from Janssen	296		296		294
AbbVie's payable to Janssen	379		379		$ 509
Janssen Biotech Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	398	518	1,210	1,497
Janssen Biotech Inc. \| Collaborative arrangement \| International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	286	265	868	816
Genentech, Inc. \| Collaborative arrangement
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	204	187	578	514
AbbVie's share of development costs (included in R&D)	29	34	87	110
Genentech, Inc. \| Collaborative arrangement \| United States
Collaborative and license agreements
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 10	$ 10	$ 27	$ 29

Goodwill and Intangible Assets - Goodwill (Details)	9 Months Ended
Goodwill and Intangible Assets - Goodwill (Details)	Sep. 30, 2022 USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 32,379,000,000
Foreign currency translation adjustments	(653,000,000)
Balance at the end of the period	31,726,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets
Gross carrying amount	$ 95,799		$ 95,799		$ 97,432
Accumulated amortization	(27,744)		(27,744)		(22,151)
Net carrying amount	68,055		68,055		75,281
Indefinite-lived intangible assets	670		670		670
Total intangible assets gross carrying amount	96,469		96,469		98,102
Intangible assets, net	68,725		68,725		75,951
Impairment of intangible assets	770		770	$ 50
Amortization expense	2,000	$ 1,900	5,728	$ 5,912
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	87,313		87,313		88,945
Accumulated amortization	(23,368)		(23,368)		(18,463)
Net carrying amount	63,945		63,945		70,482
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	8,486		8,486		8,487
Accumulated amortization	(4,376)		(4,376)		(3,688)
Net carrying amount	$ 4,110		$ 4,110		$ 4,799

Integration and Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Allergan integration plan
Restructuring charges
Integration related costs	$ 2,000		$ 2,000
Allergan integration plan \| Severance and employee benefits
Restructuring charges
Charges associated with integration or restructuring plans	5	$ 20	2	$ 55
Restructuring reserve rollforward
Accrued balance beginning of the period			222
Restructuring charges			2
Payments and other adjustments			(107)
Accrued balance end of the period	117		117
Allergan integration plan \| Severance and employee benefits \| Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	0	2	(4)	8
Allergan integration plan \| Severance and employee benefits \| Research and development
Restructuring charges
Charges associated with integration or restructuring plans	1	0	2	0
Allergan integration plan \| Severance and employee benefits \| Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	4	18	4	47
Allergan integration plan \| Other integration
Restructuring charges
Charges associated with integration or restructuring plans	111	150	327	384
Restructuring reserve rollforward
Accrued balance beginning of the period			33
Restructuring charges			316
Payments and other adjustments			(343)
Accrued balance end of the period	6		6
Allergan integration plan \| Other integration \| Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	24	44	85	84
Allergan integration plan \| Other integration \| Research and development
Restructuring charges
Charges associated with integration or restructuring plans	3	18	12	87
Allergan integration plan \| Other integration \| Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	84	88	230	213
Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	50	$ 13	143	$ 56
Restructuring reserve rollforward
Accrued balance beginning of the period			33
Restructuring charges			112
Payments and other adjustments			(25)
Accrued balance end of the period	$ 120		$ 120

Financial Instruments and Fair Value Measures - Financial Instruments (Details) € in Billions	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Sep. 30, 2019 USD ($)
Derivative instruments, notional amount and fair value
Amount excluded from the assessment of effectiveness for cash flow hedges	$ 0	$ 0
Amount excluded from the assessment of effectiveness for fair value hedges	0	$ 0
Fair value - Derivatives in asset position	569,000,000			$ 267,000,000
Fair value - Derivatives in liability position	509,000,000			37,000,000
Designated as hedging instrument \| Net investment hedges \| Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes \| €			€ 5.9		€ 5.9
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 1,800,000,000			1,100,000,000
Duration of forward exchange contracts	18 months
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	6 months
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	$ 153,000,000			51,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	9,000,000			2,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	1,000,000			0
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			0
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments \| €			€ 4.5		€ 4.3
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	70,000,000			149,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			0
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	283,000,000			15,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Net investment hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			0
Designated as hedging instrument \| Treasury rate lock agreements \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments						$ 10,000,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	750,000,000			750,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Cash flow hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	2,000,000			0
Designated as hedging instrument \| Interest rate swap contracts \| Cash flow hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			7,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	4,500,000,000			4,500,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			0
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	21,000,000			0
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			26,000,000
Designated as hedging instrument \| Interest rate swap contracts \| Fair value hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	393,000,000			15,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	6,800,000,000			8,200,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	60,000,000			26,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	$ 86,000,000			$ 13,000,000

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cost of products sold
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ 150		$ 150
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months	2		2
Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	24		24
Interest expense, net \| Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings	141	$ 5	424	$ 73
Designated as hedging instrument \| Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	431	141	932	397
Foreign currency forward exchange contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	124	43	171	67
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	362	101	748	186
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 21	$ (28)	$ 47	$ (62)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold	Cost of products sold	Cost of products sold
Foreign currency forward exchange contracts \| Designated as hedging instrument \| Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 29	$ 7	$ 67	$ 16
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Foreign currency forward exchange contracts \| Not designated as hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (121)	$ (25)	$ (285)	$ (53)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Foreign Currency Transaction Gain (Loss), before Tax	Foreign Currency Transaction Gain (Loss), before Tax	Foreign Currency Transaction Gain (Loss), before Tax	Foreign Currency Transaction Gain (Loss), before Tax
Interest rate swap contracts \| Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	$ 0	$ (1)	$ 6	$ 0
Interest rate swap contracts \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 0	$ (6)	$ (3)	$ (20)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Interest rate swap contracts \| Designated as hedging instrument \| Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (141)	$ (5)	$ (424)	$ (73)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net
Treasury rate lock agreements \| Designated as hedging instrument \| Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ 6	$ 6	$ 18	$ 18
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net	Interest Income (Expense), Nonoperating, Net

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Assets
Foreign currency contracts	$ 569	$ 267
Liabilities
Foreign currency contracts	509	37
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	62,164	82,086
Fair Value, Recurring
Assets
Cash and equivalents	11,832	9,746
Debt securities	31	46
Equity securities	72	121
Interest rate swap contracts	2	26
Total assets	12,540	10,225
Liabilities
Interest rate swap contracts	414	22
Contingent consideration	14,556	14,887
Total liabilities	15,065	14,924
Fair Value, Recurring \| Foreign currency contracts
Assets
Foreign currency contracts	567	241
Liabilities
Foreign currency contracts	95	15
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	4,303	4,451
Debt securities	0	0
Equity securities	50	100
Interest rate swap contracts	0	0
Total assets	4,353	4,551
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Fair Value, Recurring \| Significant other observable inputs (Level 2)
Assets
Cash and equivalents	7,529	5,295
Debt securities	31	46
Equity securities	22	21
Interest rate swap contracts	2	26
Total assets	8,187	5,674
Liabilities
Interest rate swap contracts	414	22
Contingent consideration	0	0
Total liabilities	509	37
Fair Value, Recurring \| Significant other observable inputs (Level 2) \| Foreign currency contracts
Assets
Foreign currency contracts	567	241
Liabilities
Foreign currency contracts	95	15
Fair Value, Recurring \| Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Interest rate swap contracts	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	14,556	14,887
Total liabilities	14,556	14,887
Fair Value, Recurring \| Significant unobservable inputs (Level 3) \| Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Money market funds and time deposits \| Fair Value, Recurring
Assets
Money market funds and time deposits	36	45
Money market funds and time deposits \| Fair Value, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Money market funds and time deposits	0	0
Money market funds and time deposits \| Fair Value, Recurring \| Significant other observable inputs (Level 2)
Assets
Money market funds and time deposits	36	45
Money market funds and time deposits \| Fair Value, Recurring \| Significant unobservable inputs (Level 3)
Assets
Money market funds and time deposits	$ 0	$ 0

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)

Sep. 30, 2022

Dec. 31, 2021

Weighted average | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

0.050

0.017

Weighted average | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

0.91

0.90

Weighted average | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1],[2]

0.98

0.96

Weighted average | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[1]

2,027

Minimum | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.041

0.002

Minimum | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.89

Minimum | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[2]

0.56

Minimum | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

2,022

Minimum | Probability of payment for royalties excluding early stage or approved indications

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.56

Maximum | Discount rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.055

0.026

Maximum | Probability of payment for unachieved milestones

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

Maximum | Probability of payment for royalties by indication

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

^[2]

Maximum | Projected year of payments

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

2,034

Maximum | Probability of payment for royalties excluding early stage or approved indications

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Significant unobservable input for contingent consideration

0.89

[1]	(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
[2]	(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at September 30, 2022 and December 31, 2021.

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Transfers of assets or liabilities between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy	$ 0
Transfers of assets out of Level 3 of the fair value hierarchy	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfers of liabilities into Level 3 of the fair value hierarchy	0
Transfers of liabilities out of Level 3 of the fair value hierarchy	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	14,887,000,000	$ 12,997,000,000
Change in fair value recognized in net earnings	647,000,000	2,447,000,000
Payments	(978,000,000)	(525,000,000)
Ending balance	$ 14,556,000,000	$ 14,919,000,000

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 143	$ 149
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,071	11,329
Long-term debt and finance lease obligations, excluding fair value hedges	53,093	70,757
Total liabilities	62,164	82,086
Book value
Liabilities
Short-term borrowings	10	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,215	12,455
Long-term debt and finance lease obligations, excluding fair value hedges	60,740	64,113
Total liabilities	69,965	76,582
Approximate fair value
Liabilities
Short-term borrowings	10	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	9,191	11,830
Long-term debt and finance lease obligations, excluding fair value hedges	53,834	71,810
Total liabilities	63,035	83,654
Approximate fair value \| Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings	0	0
Approximate fair value \| Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings	10	14
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	120	501
Long-term debt and finance lease obligations, excluding fair value hedges	741	1,053
Total liabilities	871	1,568
Approximate fair value \| Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accounts receivable, net
Concentration of Risk
Number of principal customers	3
Accounts receivable, net \| Geographic risk \| Principal US customers
Concentration of Risk
Concentrations risk (as a percent)	79.00%		75.00%
Total revenues \| HUMIRA \| Humira
Concentration of Risk
Concentrations risk (as a percent)	36.00%	37.00%

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) € in Millions, $ in Millions	1 Months Ended
	Sep. 30, 2022 USD ($)	Jul. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Jan. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	May 31, 2021 USD ($)	May 31, 2021 EUR (€)	Apr. 30, 2021 USD ($)
3.45% senior notes due 2022 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt				$ 2,900
Stated interest rate (as a percent)				3.45%
Floating rate notes due 2025 \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt			$ 2,000
Aggregate principal amount outstanding			$ 2,000
Term loan credit agreement term			5 years
Floating rate notes due 2025, refinanced \| Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross			$ 2,000
3.25% senior notes due 2022 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt		$ 1,700
Stated interest rate (as a percent)		3.25%
Senior Notes Due 2022 At 3.20 Percent \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt	$ 1,000
Stated interest rate (as a percent)	3.20%
2.30% senior notes due 2021 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt								$ 1,800
Stated interest rate (as a percent)								2.30%
0.50% senior euro notes due 2021 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt \| €							€ 750
Stated interest rate (as a percent)						0.50%	0.50%
Floating senior notes due 2021 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt						$ 750
Floating rate notes due 2023 \| Term loan facilities
Debt and Credit Facilities [Line Items]
Repayments of long-term debt					$ (1,000)
Aggregate principal amount outstanding					$ 1,000
Term loan credit agreement term					3 years
Floating rate notes due 2023, refinanced \| Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross					$ 1,000
5.0% senior notes due 2021 \| Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt					$ (1,200)
Stated interest rate (as a percent)					5.00%

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 113	$ 110	$ 342	$ 331
Interest cost	74	59	223	177
Expected return on plan assets	(177)	(166)	(536)	(498)
Amortization of prior service cost (credit)	1	1	2	2
Amortization of actuarial loss	57	72	173	217
Net periodic benefit cost	68	76	204	229
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	13	12	38	36
Interest cost	6	5	18	14
Expected return on plan assets	0	0	0	0
Amortization of prior service cost (credit)	(10)	(10)	(29)	(29)
Amortization of actuarial loss	7	8	20	24
Net periodic benefit cost	$ 16	$ 15	$ 47	$ 45

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 126	$ 135	$ 539	$ 563
Tax benefit	25	27	102	101
After-tax compensation expense	101	108	437	462
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	8	9	33	39
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	47	47	194	181
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 71	$ 79	$ 312	$ 343

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) \| shares	0.9
Weighted-average grant-date fair value of the stock options granted (in dollars per share) \| $ / shares	$ 22.83
Unrecognized compensation cost \| $	$ 8
Period for recognition of unrecognized compensation cost	2 years

Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares) \| shares	5.9
Fair market value of awards vested (in dollars per share) \| $ / shares	$ 146.30
Unrecognized compensation cost \| $	$ 692
Period for recognition of unrecognized compensation cost	2 years

Equity - Cash Dividends (Details) - $ / shares	Oct. 28, 2022	Sep. 09, 2022	Jun. 23, 2022	Feb. 17, 2022	Oct. 29, 2021	Sep. 10, 2021	Jun. 17, 2021	Feb. 18, 2021
Dividends Payable
Cash dividends declared per common share (in dollars per share)		$ 1.41	$ 1.41	$ 1.41	$ 1.41	$ 1.30	$ 1.30	$ 1.30
Subsequent event
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.48

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 4	$ 6	$ 1,483	$ 803
Remaining share repurchase authorization amount	$ 1,400		$ 1,400
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Shares repurchased (in shares)			8	5
Payment for shares repurchased			$ 1,100	$ 550

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	$ 14,688	$ 12,594	$ 15,436	$ 13,097
Other comprehensive loss	(247)	(53)	(544)	(39)
Ending balance	16,027	13,577	16,027	13,577
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(570)	583
Other comprehensive income (loss) before reclassifications			(2,043)	(794)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Other comprehensive loss			(2,043)	(794)
Ending balance	(2,613)	(211)	(2,613)	(211)
Net investment hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(91)	(790)
Other comprehensive income (loss) before reclassifications			1,318	457
Net losses (gains) reclassified from accumulated other comprehensive loss			(53)	(13)
Other comprehensive loss			1,265	444
Ending balance	1,174	(346)	1,174	(346)
Pension and post-employment benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(2,546)	(3,067)
Other comprehensive income (loss) before reclassifications			6	27
Net losses (gains) reclassified from accumulated other comprehensive loss	43	56	130	169
Other comprehensive loss			136	196
Ending balance	(2,410)	(2,871)	(2,410)	(2,871)
Cash flow hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			308	157
Other comprehensive income (loss) before reclassifications			151	60
Net losses (gains) reclassified from accumulated other comprehensive loss			(53)	55
Other comprehensive loss			98	115
Ending balance	406	272	406	272
Accumulated other comprehensive income (loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(2,899)	(3,117)
Other comprehensive income (loss) before reclassifications			(568)	(250)
Net losses (gains) reclassified from accumulated other comprehensive loss			24	211
Other comprehensive loss			(544)	(39)
Ending balance	$ (3,443)	$ (3,156)	$ (3,443)	$ (3,156)

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

$ 497

$ 585

$ 1,568

$ 1,813

Tax expense (benefit)

448

508

1,139

1,214

Total reclassifications, net of tax

(3,949)

(3,179)

(9,363)

(7,498)

Losses (gains) on foreign currency forward exchange contracts

5,022

4,390

13,244

13,126

Pension and post-employment benefits

Significant amounts reclassified out of each component of AOCI

Amortization of actuarial losses and other

^[1]

166

214

Tax benefit

(12)

(15)

(36)

(45)

Total reclassifications, net of tax

130

169

Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Total reclassifications, net of tax

(53)

Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Tax expense (benefit)

(4)

(9)

Total reclassifications, net of tax

(23)

(53)

Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

(29)

(7)

(67)

(16)

Tax expense (benefit)

Total reclassifications, net of tax

(23)

(6)

(53)

(13)

Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Losses (gains) on foreign currency forward exchange contracts

^[3]

(21)

(47)

Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

(6)

(18)

Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities

Significant amounts reclassified out of each component of AOCI

Gains on derivative amount excluded from effectiveness testing

^[2]

$ 0

$ 6

$ 3

$ 20

[1]	(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
[2]	(a) Amounts are included in interest expense, net (see Note 8)
[3]	(c) Amounts are included in cost of products sold (see Note 8).

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	10.00%	14.00%	11.00%	14.00%
U.S. statutory tax rate	21.00%	21.00%	21.00%	21.00%
Potential change in unrecognized tax benefits	$ 141		$ 141

Legal Proceedings and Contingencies (Details) $ in Billions	1 Months Ended				3 Months Ended	9 Months Ended
Legal Proceedings and Contingencies (Details) $ in Billions	Feb. 28, 2022 investment_fund	Jan. 31, 2022 investment_fund	Aug. 31, 2019 company	Jun. 30, 2016 investment_fund	May 31, 2019 company	Sep. 30, 2022 USD ($) lawsuit claim	Sep. 30, 2022 USD ($) class_action claim	Sep. 30, 2022 USD ($) direct_purchaser claim	Sep. 30, 2022 USD ($) end_payor_purchaser claim	Sep. 30, 2022 USD ($) company claim
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit						4
Number of purported class actions \| class_action							2
Number of healthcare benefit providers acting as plaintiff in lawsuit								1	1
AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into			3
Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation
Legal Proceedings and Contingencies
Number of individual putative class action lawsuits					12
Bystolic antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into										6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending \| claim						3,083	3,083	3,083	3,083	3,083
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending \| claim						284	284	284	284	284
Prescription drug abuse litigation in state courts \| Selling, general and administrative
Legal Proceedings and Contingencies
Litigation charge related to potential settlement \| $						$ 2.1	$ 2.1	$ 2.1	$ 2.1	$ 2.1
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) \| investment_fund				5
Number of plaintiff claims dismissed \| investment_fund	3	1

Segment Information - Additional Information (Details)	9 Months Ended
Segment Information - Additional Information (Details)	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue
Total net revenues	$ 14,812	$ 14,342	$ 42,933	$ 41,311
All other
Disaggregation of Revenue
Net revenues	925	1,117	3,145	3,814
Immunology \| Humira
Disaggregation of Revenue
Net revenues	5,559	5,425	15,658	15,360
Immunology \| Humira \| United States
Disaggregation of Revenue
Net revenues	4,956	4,613	13,613	12,777
Immunology \| Humira \| International
Disaggregation of Revenue
Net revenues	603	812	2,045	2,583
Immunology \| Skyrizi
Disaggregation of Revenue
Net revenues	1,397	796	3,589	2,044
Immunology \| Skyrizi \| United States
Disaggregation of Revenue
Net revenues	1,221	679	3,081	1,725
Immunology \| Skyrizi \| International
Disaggregation of Revenue
Net revenues	176	117	508	319
Immunology \| Rinvoq
Disaggregation of Revenue
Net revenues	695	453	1,752	1,134
Immunology \| Rinvoq \| United States
Disaggregation of Revenue
Net revenues	505	348	1,228	889
Immunology \| Rinvoq \| International
Disaggregation of Revenue
Net revenues	190	105	524	245
Hematologic Oncology \| Imbruvica
Disaggregation of Revenue
Net revenues	1,135	1,374	3,453	4,023
Hematologic Oncology \| Imbruvica \| United States
Disaggregation of Revenue
Net revenues	849	1,109	2,585	3,207
Hematologic Oncology \| Imbruvica \| International
Disaggregation of Revenue
Collaboration revenues	286	265	868	816
Hematologic Oncology \| Venclexta
Disaggregation of Revenue
Net revenues	515	492	1,493	1,332
Hematologic Oncology \| Venclexta \| United States
Disaggregation of Revenue
Net revenues	259	237	740	685
Hematologic Oncology \| Venclexta \| International
Disaggregation of Revenue
Net revenues	256	255	753	647
Aesthetics \| Botox Cosmetic
Disaggregation of Revenue
Net revenues	637	545	1,973	1,606
Aesthetics \| Botox Cosmetic \| United States
Disaggregation of Revenue
Net revenues	370	356	1,232	1,027
Aesthetics \| Botox Cosmetic \| International
Disaggregation of Revenue
Net revenues	267	189	741	579
Aesthetics \| Juvederm Collection
Disaggregation of Revenue
Net revenues	352	354	1,106	1,103
Aesthetics \| Juvederm Collection \| United States
Disaggregation of Revenue
Net revenues	125	159	420	478
Aesthetics \| Juvederm Collection \| International
Disaggregation of Revenue
Net revenues	227	195	686	625
Aesthetics \| Other Aesthetics
Disaggregation of Revenue
Net revenues	312	352	967	1,117
Aesthetics \| Other Aesthetics \| United States
Disaggregation of Revenue
Net revenues	265	305	837	968
Aesthetics \| Other Aesthetics \| International
Disaggregation of Revenue
Net revenues	47	47	130	149
Neuroscience \| Botox Therapeutic
Disaggregation of Revenue
Net revenues	699	645	1,991	1,780
Neuroscience \| Botox Therapeutic \| United States
Disaggregation of Revenue
Net revenues	584	534	1,641	1,451
Neuroscience \| Botox Therapeutic \| International
Disaggregation of Revenue
Net revenues	115	111	350	329
Neuroscience \| Vraylar \| United States
Disaggregation of Revenue
Net revenues	554	461	1,473	1,239
Neuroscience \| Duodopa
Disaggregation of Revenue
Net revenues	110	127	351	383
Neuroscience \| Duodopa \| United States
Disaggregation of Revenue
Net revenues	22	23	72	73
Neuroscience \| Duodopa \| International
Disaggregation of Revenue
Net revenues	88	104	279	310
Neuroscience \| Ubrelvy \| United States
Disaggregation of Revenue
Net revenues	160	162	483	369
Neuroscience \| Qulipta \| United States
Disaggregation of Revenue
Net revenues	62	0	106	0
Neuroscience \| Other Neuroscience
Disaggregation of Revenue
Net revenues	87	171	414	502
Neuroscience \| Other Neuroscience \| United States
Disaggregation of Revenue
Net revenues	82	166	400	489
Neuroscience \| Other Neuroscience \| International
Disaggregation of Revenue
Net revenues	5	5	14	13
Eye Care \| Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	121	138	391	430
Eye Care \| Lumigan/Ganfort \| United States
Disaggregation of Revenue
Net revenues	59	63	186	201
Eye Care \| Lumigan/Ganfort \| International
Disaggregation of Revenue
Net revenues	62	75	205	229
Eye Care \| Alphagan/Combigan
Disaggregation of Revenue
Net revenues	73	128	272	388
Eye Care \| Alphagan/Combigan \| United States
Disaggregation of Revenue
Net revenues	37	89	161	271
Eye Care \| Alphagan/Combigan \| International
Disaggregation of Revenue
Net revenues	36	39	111	117
Eye Care \| Restasis
Disaggregation of Revenue
Net revenues	142	319	556	926
Eye Care \| Restasis \| United States
Disaggregation of Revenue
Net revenues	132	305	518	884
Eye Care \| Restasis \| International
Disaggregation of Revenue
Net revenues	10	14	38	42
Eye Care \| Other Eye Care
Disaggregation of Revenue
Net revenues	287	286	892	863
Eye Care \| Other Eye Care \| United States
Disaggregation of Revenue
Net revenues	134	128	400	375
Eye Care \| Other Eye Care \| International
Disaggregation of Revenue
Net revenues	153	158	492	488
Other Key Products \| Mavyret
Disaggregation of Revenue
Net revenues	383	426	1,161	1,283
Other Key Products \| Mavyret \| United States
Disaggregation of Revenue
Net revenues	190	183	562	557
Other Key Products \| Mavyret \| International
Disaggregation of Revenue
Net revenues	193	243	599	726
Other Key Products \| Creon \| United States
Disaggregation of Revenue
Net revenues	336	310	941	864
Other Key Products \| Linzess/Constella
Disaggregation of Revenue
Net revenues	271	261	766	751
Other Key Products \| Linzess/Constella \| United States
Disaggregation of Revenue
Net revenues	262	253	742	728
Other Key Products \| Linzess/Constella \| International
Disaggregation of Revenue
Net revenues	$ 9	$ 8	$ 24	$ 23